VLP-based Vaccine Development for SARS-CoV-2

Virus-like particle (VLP) is a polymeric nanostructure assembled from natural viral structural proteins, but do not contain any genetic material. The VLP consists of high-density displays of viral surface proteins and is therefore a highly adaptable tool for a variety of applications, such as delivery system, antibody development, and membrane protein expression. During the coronavirus pandemic, Creative Biostructure rapidly integrated VLP-based vaccine development technologies and various in-house coronavirus-related VLP products to facilitate the development of methods for the prevention of this emerging infectious disease.